[Changchun Hi-Tech: existing long-acting growth hormone products are expected to be listed on the US market in 2027] Changchun Hi-Tech said on the interactive platform that for the US market, the existing long-acting growth hormone products will directly declare the clinical III phase, which is expected to be completed in 2025 and launched in 2027; at the same time, the new generation of long-acting products under development is expected to launch American clinical trials by the end of next year.